An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Melanoma, skin | Urinary Bladder
What is the purpose of this trial?
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
- Ages18 years and older
- Trial withReplimune Inc.
- Start Date10/11/2019
- End Date11/29/2021
- Last Updated11/25/2019
- Study HIC#2000024206